Depatuxizumab mafodotin | EGFR inhibitor | Read Reviews & Product Use Citations

Depatuxizumab Mafodotin (Depatux-M, ABT-414) is an antibody-drug conjugate consisting of an EGFR IGg1 monoclonal antibody conjugated to the tubulin inhibitor monomethyl auristatin F via a stable maleimidocaproyl link. Depatuxizumab Mafodotin is used in the treatment of recurrent EGFR-amplified Glioblastoma (GBM).

CAS No. 1585973-65-4

Click to purchase products related to Depatuxizumab mafodotin

Purity & Quality Control

Batch: D404201 Purity: 98.38% Protein concentration: 5.52mg/ml Endotoxin Level: ＜1EU/mg

98.38

Choose Selective EGFR Inhibitors

Biological Activity

Description	Depatuxizumab Mafodotin (Depatux-M, ABT-414) is an antibody-drug conjugate consisting of an EGFR IGg1 monoclonal antibody conjugated to the tubulin inhibitor monomethyl auristatin F via a stable maleimidocaproyl link. Depatuxizumab Mafodotin is used in the treatment of recurrent EGFR-amplified Glioblastoma (GBM).

References
[1] Padovan M, et al. Cancers (Basel). 2021 Jun 3;13(11):2773.

References

[1] Padovan M, et al. Cancers (Basel). 2021 Jun 3;13(11):2773.

Product Details

CAS No.	1585973-65-4
ADC antiody	Depatuxizumab
ADC linker	Maleimidocaproyl (mc) linker
ADC cytotoxin	MMAF
Formulation	1xPBS
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field